The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Bharat Biotech expects to share further details of the trial results as additional data become available.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
